search
Back to results

Hyperphosphatemia in Children With Chronic Kidney Disease

Primary Purpose

Hyperphosphatemia

Status
Unknown status
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Calcium acetate and sevelamer hydrochloride
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hyperphosphatemia

Eligibility Criteria

6 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children aged from 6 to 18 years
  • With end stage renal disease on regular hemodialysis,
  • With hyperphosphatemia (serum phosphorus > 4.5mg/dL ).
  • Both genders will be included
  • Given informed concent.

Exclusion Criteria:

  • - Children < 6 years,
  • Severe Gastrointestinal disorder,
  • Known hypersensitivity to phosphate binders,
  • Inability or rejection to give informed consent,
  • Normal serum phosphate level.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Placebo Comparator

    Experimental

    Arm Label

    calcium group

    sevelamer group

    Arm Description

    will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months. all the following investigation will be done before and after consecutive 3 months of administration : Complete blood count Kidney function tests (serum urea and creatinine) Serum total calcium level. Serum phosphorus level. Calcium × phosphorus product. Serum parathormone level. Serum alkaline phosphatase level. Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides). Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug

    will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months. all the following investigation will be done before and after consecutive 3 months of administration : Complete blood count Kidney function tests (serum urea and creatinine) Serum total calcium level. Serum phosphorus level. Calcium × phosphorus product. Serum parathormone level. Serum alkaline phosphatase level. Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides). Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug

    Outcomes

    Primary Outcome Measures

    controlling of hyperphosphatemia
    controlling abnormal laboratory parameters such as calcium, phosphate, and parathyroid hormone .
    Cardiovascular complications
    Preventing cardiovascular complication in children with chronic kidney disease

    Secondary Outcome Measures

    Full Information

    First Posted
    June 20, 2017
    Last Updated
    June 27, 2017
    Sponsor
    Assiut University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03202407
    Brief Title
    Hyperphosphatemia in Children With Chronic Kidney Disease
    Official Title
    Effect of Non-calcium Phosphate Binders Versus Calcium Based Binders on Chronic Kidney Disease -Mineral and Bone Disorder in Children on Regular Hemodialysis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2017
    Overall Recruitment Status
    Unknown status
    Study Start Date
    August 1, 2017 (Anticipated)
    Primary Completion Date
    August 1, 2018 (Anticipated)
    Study Completion Date
    December 1, 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Assiut University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    "Chronic Kidney Disease-Mineral and Bone Disorder " is a systemic disorder of mineral and bone metabolism, due to chronic kidney disease that is manifested by either one or a combination of the following : Abnormalities of calcium, phosphate, parathyroid hormone or vitamin D metabolism Vascular and/or soft tissue calcification. Abnormalities in bone turnover, metabolism, volume, linear growth or strength. According to glomerular filtration rate , Kidney Disease Improving Global Outcomesclassify chronic kidney disease into 5 stages,stage 5 also known as End Stage Renal disease is defined as glomerular filtration rate less than 15 ml/Min/1.73 m2, or the need for renal replacement therapy for survival The kidney plays a major role in phosphate homoeostasis. The kidneys excrete the total net amount of absorbed phosphate.Under normal physiological condition phosphate is freely filtered through the glomerulus. The majority (85-90%) of filtered phosphate undergoes tubular reabsorption primarily in proximal tubules. Progressive renal insufficiency leads to hyperphosphatemia, hypocalcemia, and secondary hyperparathyroidism . Hyperphosphatemia known as hidden killer in chronic kidney disease defined as an abnormally high serum phosphate concentration of >1.46 mmol/L (4.5 mg/dL). Its long term complications are renal osteodystrophy, hyperparathyroidism, and increased cardiovascular calcification leading to increased mortality and morbidity . High serum phosphate can interact with calcium to precipitate calcium phosphate salts in non-skeletal tissues Calcification generally occurs in the blood vessels, heart valves, myocardium, and other soft tissues . Cardiovascular calcification is probably the main reason for the high prevalence of cardiovascular diseases in chronic kidney disease patients Studies have shown that hyperphosphatemia is associated with increased vascular stiffening and arterial and valvular calcification This is postulated to be caused by elevated serum phosphorus promoting the transformation of vascular smooth muscle cells into an osteoblast phenotype that can mineralize These vascular calcification also lead to left ventricular hypertrophy by decreasing vascular compliance . Poor control of mineral metabolism also has been associated with functional and structural cardiac abnormalities Efforts to reduce morbidity and mortality associated with Chronic Kidney Disease-Mineral and Bone Disorder are therefore primarily directed at controlling hyperphosphatemia via diet, phosphorus binders, and dialysis Dialysis alone is inadequate in assisting hemodialysis patients to obtain and maintain normal serum phosphate levels . So, other methods of achieving prescribed levels of serum phosphate in hemodialysis patients include the use of phosphate binders and phosphorus dietary restrictions.: Phosphate binders have been approved by the Federal Drug Administration (FDA) for patients treated with maintenance dialysis, and calcium-containing salts are used worldwide not only for the control of hyperphosphatemia but also as a source of supplemental calcium. Several calcium salts are commercially available, including calcium carbonate, calcium acetate, and calcium citrate Sevelamer hydrochloride is a recently developed phosphate binder, which is a quaternary amine anion exchanger without calcium or aluminum. Sevelamer is effective in controlling hyperphosphatemia without increasing the calcium load in chronic hemodialysis patients In addition to its effects on serum phosphorous levels, sevelamer has been shown to decrease total serum cholesterol and low-density lipoprotein cholesterol and to increase high-density lipoprotein levels . These effects may offer additional benefits in reducing cardiovascular complications in patients with end-stage renal disease. Controlling abnormal laboratory parameters such as calcium ,phosphate and parathyroid hormone as well as preventing the progression of extraskeletal calcification is considered a major component for prevention of the bone disease and other related morbidities and hopefully mortality in chronic kidney disease patients

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hyperphosphatemia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Model Description
    parallel group
    Masking
    Participant
    Masking Description
    single blinded
    Allocation
    Randomized
    Enrollment
    40 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    calcium group
    Arm Type
    Placebo Comparator
    Arm Description
    will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months. all the following investigation will be done before and after consecutive 3 months of administration : Complete blood count Kidney function tests (serum urea and creatinine) Serum total calcium level. Serum phosphorus level. Calcium × phosphorus product. Serum parathormone level. Serum alkaline phosphatase level. Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides). Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug
    Arm Title
    sevelamer group
    Arm Type
    Experimental
    Arm Description
    will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months. all the following investigation will be done before and after consecutive 3 months of administration : Complete blood count Kidney function tests (serum urea and creatinine) Serum total calcium level. Serum phosphorus level. Calcium × phosphorus product. Serum parathormone level. Serum alkaline phosphatase level. Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides). Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug
    Intervention Type
    Drug
    Intervention Name(s)
    Calcium acetate and sevelamer hydrochloride
    Intervention Description
    receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
    Primary Outcome Measure Information:
    Title
    controlling of hyperphosphatemia
    Description
    controlling abnormal laboratory parameters such as calcium, phosphate, and parathyroid hormone .
    Time Frame
    3 months
    Title
    Cardiovascular complications
    Description
    Preventing cardiovascular complication in children with chronic kidney disease
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Years
    Maximum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Children aged from 6 to 18 years With end stage renal disease on regular hemodialysis, With hyperphosphatemia (serum phosphorus > 4.5mg/dL ). Both genders will be included Given informed concent. Exclusion Criteria: - Children < 6 years, Severe Gastrointestinal disorder, Known hypersensitivity to phosphate binders, Inability or rejection to give informed consent, Normal serum phosphate level.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Amed roshdy, professor
    Phone
    01001998013
    Email
    ahmedroshdy2@hotmail.com

    12. IPD Sharing Statement

    Learn more about this trial

    Hyperphosphatemia in Children With Chronic Kidney Disease

    We'll reach out to this number within 24 hrs